HIV, STI, and Hepatitis Among People Who Inject Drugs at a Sexual Health Clinic in Melbourne, Australia: 2012 to 2022 - Summary - MDSpire

HIV, STI, and Hepatitis Among People Who Inject Drugs at a Sexual Health Clinic in Melbourne, Australia: 2012 to 2022

  • By

  • Tiffany R Phillips

  • Esha Abraham

  • Christopher K Fairley

  • Rayner Kay Jin Tan

  • Ei T Aung

  • Jason J Ong

  • Eric P F Chow

  • June 13, 2025

  • 0 min

Share

Objective:

To examine sexual practices and STI positivity among people who inject drugs (PWID) over a decade, with a focus on differences between men who have sex with women only (MSWO), gay or bisexual men who have sex with men (gbMSM), and women.

Key Findings:
  • Significant rise in syphilis positivity from 0.6% in 2012/2013 to 10.0% in 2020/2021 (Ptrend = .0033).
  • gbMSM had higher overall infection positivity (29.1%) compared to MSWO (19.8%) and women (17.0%; P < .001).
  • Positivity rates for new HIV (2.6%), infectious syphilis (6.8%), gonorrhea (8.6%), chlamydia (8.7%), HBV (0.6%), and HCV (10.0%) were reported.
Interpretation:

PWID are highly susceptible to STIs and blood-borne infections, with gbMSM showing particularly high rates of infection, indicating a need for targeted interventions.

Limitations:
  • Study limited to clients attending a single sexual health clinic, which may not represent all PWID.
  • Exclusion of transgender individuals and those who declined to provide partner information may limit generalizability and impact findings.
Conclusion:

Future prevention programs must enhance HCV testing rates and address sexual risk practices, such as promoting condom use and safe injecting practices, to reduce disease burden among PWID.

Original Source(s)

Related Content